Your browser doesn't support javascript.
loading
Clinical efficacy of alternative TNF inhibitor and secukinumab between primary non-responder and secondary non-responder of prior TNF inhibitor in ankylosing spondylitis.
Min, Hong Ki; Kim, Hae-Rim; Lee, Sang-Heon; Hong, Yeon Sik; Kim, Moon-Young; Park, Sung-Hwan; Kang, Kwi Young.
  • Min HK; Department of Internal Medicine, Division of Rheumatology, Konkuk University Medical Center, 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea.
  • Kim HR; Department of Internal Medicine, Division of Rheumatology, Research Institute of Medical Science, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea.
  • Lee SH; Department of Internal Medicine, Division of Rheumatology, Research Institute of Medical Science, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul, South Korea.
  • Hong YS; Department of Internal Medicine, Division of Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Kim MY; Department of Internal Medicine, Division of Rheumatology, Incheon Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, South Korea.
  • Park SH; Department of Internal Medicine, Division of Rheumatology, Incheon Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, South Korea.
  • Kang KY; Department of Internal Medicine, Division of Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Mod Rheumatol ; 33(1): 194-201, 2023 Jan 03.
Article en En | MEDLINE | ID: mdl-35107167

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Productos Biológicos / Antirreumáticos Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Productos Biológicos / Antirreumáticos Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article